SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001157601

MDGL

MADRIGAL PHARMACEUTICALS, INC.
$499.40 ▼ -0.06%
Prev close $499.71
Market cap$11.6B
ConsensusStrong Buy
12-mo target$682.11 (+36.6%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)29 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MDGL right now — valuation, ownership and activity at a glance.
Market Cap
$11.6B
Cap Size
Large Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$11.1B
Inst. Activity
29 buys / 21 sells
Insider Activity
$0.00 buy / $7.9M sell
Insider Net $
-$7.9M
SEC Reports
8
Press Releases
1
Price chart 30d -8.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 16, 2026 other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL),
Sep 11, 2026 Insider
Sibold William John sold 60 shares
President and CEO @ $533.09 ($32.0K)
Sep 11, 2026 Insider
Sibold William John sold 218 shares
President and CEO @ $535.94 ($116.8K)
Sep 11, 2026 Insider
Sibold William John sold 368 shares
President and CEO @ $541.64 ($199.3K)
Aug 12, 2026 SEC
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board o
8-K — Impact 3/10
Jul 30, 2026 SEC
Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consensus revenue estimate
8-K — Impact 7/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
401,708 shares ($215.7M)
Jun 30, 2026 Inst.
FMR LLC — TRIM
356,201 shares ($191.3M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 92% rate it Buy or better · 24 analysts
Strong Buy 6 25% Buy 16 67% Hold 2 8% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 23, 2026CitigroupINITIATEBuy 55%
Aug 4, 2026Wolfe ResearchUPGRADEOutperform 52%
Aug 3, 2026BarclaysMAINTAINOverweight 54%
Jul 29, 2026Canaccord GenuityMAINTAINBuy 47%
Jul 27, 2026Wells FargoINITIATEOverweight 54%
Jun 11, 2026B of A SecuritiesMAINTAINNeutral 54%
May 13, 2026Truist SecuritiesMAINTAINBuy 55%
May 7, 2026Canaccord GenuityMAINTAINBuy 47%
May 7, 2026Evercore ISI GroupMAINTAINOutperform 59%
May 6, 2026HC Wainwright & Co.REITERATEBuy 43%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202661620092%
Aug 1, 202651630088%
Jul 1, 202651530087%
Jun 1, 202651530087%
May 1, 202651530087%
Apr 1, 202651530087%
Mar 1, 202651530087%
Feb 1, 202651630088%
Price targets
Where 18 covering analysts think MDGL trades over the next 12 months.
$682.11 +36.6% upside Strong Buy
Current$499.40 Low$543.00 Median$661.00 High$962.00 18 analysts
$543.00$962.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 2 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 4.0/10.Plus 1 press releases.
NEUTRAL8-K3/10
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Joh
Aug 12, 2026
BULLISH8-K7/10
Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consen
Jul 30, 2026
NEUTRALCLUSTER3/10
Two Madrigal insiders (Director Levy and CMO Soergel) sold a combined $456K in open-market transacti
May 22, 2026
BULLISH8-K7/10
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consen
May 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 16, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering
Sep 10, 2026
Clinical Trial
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 10, 2026
clinical_trial_readout
T-90d Trial Readout: Resmetirom (Phase 3)
Trial: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOM
Sep 7, 2026
dark_pool
Dark Pool: MDGL — 0.3M shares, 18,897 trades
Week starting 2026-09-07. Total ATS volume: 321,892 shares across 18,897 trades.
Sep 2, 2026
clinical_trial_readout
T-90d Trial Readout: Resmetirom (Phase 3)
Trial: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-1.09$-1.38–$-0.5678.1%+0.0%—$0.4B4
Next Q$-0.42$-0.77–$0.1183.6%+0.0%—$0.4B4
Current FY$-6.49$-7.38–$-4.9149.0%+0.0%—$1.5B4
Next FY$9.63$7.01–$12.84248.3%+0.0%2↑ 1↓$2.1B4
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-1.087—
7d ago$-1.087—
30d ago$-1.087—
60d ago$-1.033-0.054
90d ago$-1.033-0.054
Institutional ownership
Which big funds own MDGL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $11.1B total value (20,590,230 shares) as of 2026-Q2. Top holders: NOMURA, BAKER, RTW. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
NOMURA ASSET MANAGEMENT CO LTD0$0.000.0%—
BAKER BROS. ADVISORS LP2,143,131$1.2B10.4%—
RTW INVESTMENTS, LP1,993,687$1.1B9.7%—
Jupiter Topco LLC1,936,099$1.0B9.4%—
Avoro Capital Advisors LLC1,833,333$984.4M8.9%—
PAULSON & CO. INC.1,340,020$719.5M6.5%—
BlackRock, Inc.1,200,770$644.8M5.8%—
VANGUARD CAPITAL MANAGEMENT LLC835,668$448.7M4.1%—
WELLINGTON MANAGEMENT GROUP LLP825,714$443.4M4.0%—
VANGUARD PORTFOLIO MANAGEMENT LLC781,731$419.8M3.8%—
Recent position changes
FundActionPrevCurrentChangeValue
UBS Group AGDOUBLED117,779401,708+241.1%$215.7M
FMR LLCTRIM511,728356,201-30.4%$191.3M
AMERIPRISE FINANCIAL INCDOUBLED98,181231,205+135.5%$124.1M
NORGES BANKNEW—213,886—$114.8M
JANE STREET GROUP, LLCDOUBLED35,838191,541+434.5%$102.8M
ALLIANCEBERNSTEIN L.P.ADD125,447189,458+51.0%$99.2M
TORONTO DOMINION BANKADD130,460181,432+39.1%$97.4M
Hood River Capital Management LLCTRIM249,511169,084-32.2%$90.8M
Holocene Advisors, LPNEW—152,924—$82.1M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED22,216148,610+568.9%$79.8M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$7.9M — $0.00 bought, $7.9M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 11, 2026Sibold William JohnPresident and CEOSELL60$533.09$32.0K
Sep 11, 2026Sibold William JohnPresident and CEOSELL218$535.94$116.8K
Sep 11, 2026Sibold William JohnPresident and CEOSELL368$541.64$199.3K
Sep 11, 2026Sibold William JohnPresident and CEOSELL1,539$544.02$837.3K
Sep 11, 2026Sibold William JohnPresident and CEOSELL106$534.06$56.6K
Sep 11, 2026Sibold William JohnPresident and CEOSELL1,202$542.60$652.2K
Sep 11, 2026Sibold William JohnPresident and CEOSELL160$537.62$86.0K
Sep 11, 2026Sibold William JohnPresident and CEOSELL687$540.59$371.4K
Sep 11, 2026Sibold William JohnPresident and CEOSELL120$546.38$65.6K
Sep 11, 2026Sibold William JohnPresident and CEOSELL761$544.83$414.6K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MDGL.
Shares short
2,254,423
Settlement Sep 15, 2026
Change vs prior
+0.6%
Semi-monthly cycle
Days to cover
11.4
At avg daily volume
Of shares outstanding
≈9.8%
Estimate — not % of float
All MDGL filing & press-release reports (9)